204
Views
26
CrossRef citations to date
0
Altmetric
Technology Evaluation

Pathway analysis software as a tool for drug target selection, prioritization and validation of drug mechanism

&
Pages 411-421 | Published online: 14 Feb 2007

Bibliography

  • SCHENA M, SHALON D, DAVIS RW, BROWN PO: Quantitative monitoring of gene expression patterns with a complementary DNA microarray. Science (1995) 270(5235):467-470.
  • SCHENA M, SHALON D, HELLER R et al.: Parallel human genome analysis: microarray-based expression monitoring of 1000 genes. Proc. Natl. Acad. Sci. USA (1996) 93(20):10614-10619.
  • LOCKHART DJ, DONG H, BYRNE MC et al.: Expression monitoring by hybridization to high-density oligonucleotide arrays. Nat. Biotech. (1996) 14(13):1675.
  • STEARS RL, MARTINSKY T, SCHENA M: Trends in microarray analysis. Nat. Med. (2003) 9(1):140-145.
  • ZHU H, BILGIN M, BANGHAM R et al.: Global analysis of protein activities using proteome chips. Science (2001) 293(5537):2101-2105.
  • MENDOZA LG, MCQUARY P, MONGAN A et al.: High-throughput microarray-based enzyme-linked immunosorbent assay (ELISA). Biotechniques (1999) 27(4):778-780, 782-776, 788.
  • ZHU H, SNYDER M: Protein arrays and microarrays. Curr. Opin. Chem. Biol. (2001) 5(1):40-45.
  • SYDOR JR, NOCK S: Protein expression profiling arrays: tools for the multiplexed high-throughput analysis of proteins. Proteome Sci. (2003) 1(1):3.
  • KINGSMORE SF: Multiplexed protein measurement: technologies and applications of protein and antibody arrays. Nat. Rev. Drug Discov. (2006) 5(4):310-320.
  • AEBERSOLD R, MANN M: Mass spectrometry-based proteomics. Nature (2003) 422(6928):198-207.
  • LEGRAIN P, SELIG L: Genome-wide protein interaction maps using two-hybrid systems. FEBS Lett. (2000) 480(1):32-36.
  • KURDISTANI SK, GRUNSTEIN M: In vivo protein-protein and protein-DNA crosslinking for genomewide binding microarray. Methods (2003) 31(1):90-95.
  • ROBYR D, GRUNSTEIN M: Genomewide histone acetylation microarrays. Methods (2003) 31(1):83-89.
  • DRUKER BJ, LYDON NB: Lessons learned from the development of an Abl tyrosine kinase inhibitor for chronic myelogenous leukemia. J. Clin. Invest. (2000) 105(1):3-7.
  • DEININGER MWN, DRUKER BJ: Specific targeted therapy of chronic myelogenous leukemia with imatinib. Pharmacol. Rev. (2003) 55(3):401-423.
  • NOWELL PC, HUNGERFORD DA: Chromosome studies on normal and leukemic human leukocytes. J. Natl. Cancer Inst. (1960) 25:85-109.
  • DE KLEIN A, VAN KESSEL AG, GROSVELD G et al.: A cellular oncogene is translocated to the Philadelphia chromosome in chronic myelocytic leukaemia. Nature (1982) 300(5894):765-767.
  • GROFFEN J, STEPHENSON JR, HEISTERKAMP N et al.: Philadelphia chromosomal breakpoints are clustered within a limited region, bcr, on chromosome 22. Cell (1984) 36(1):93-99.
  • LUGO TG, PENDERGAST AM, MULLER AJ, WITTE ON: Tyrosine kinase activity and transformation potency of bcr-abl oncogene products. Science (1990) 247(4946):1079-1082.
  • DRUKER BJ, TAMURA S, BUCHDUNGER E et al.: Effects of a selective inhibitor of the Abl tyrosine kinase on the growth of Bcr-Abl positive cells. Nat. Med. (1996) 2(5):561-566.
  • NOBLE MEM, ENDICOTT JA, JOHNSON LN: Protein kinase inhibitors: insights into drug design from structure. Science (2004) 303(5665):1800-1805.
  • SJOBLOM T, JONES S, WOOD LD et al.: The consensus coding sequences of human breast and colorectal cancers. Science (2006) 314(5797):268-274.
  • KERKELA R, GRAZETTE L, YACOBI R et al.: Cardiotoxicity of the cancer therapeutic agent imatinib mesylate. Nat. Med. (2006) 12(8):908-916.
  • HATFIELD A, OWEN S, PILOT PR et al.: In reply to ‘Cardiotoxicity of the cancer therapeutic agent imatinib mesylate’. Nat. Med. (2007) 13(1):13,13-14,14,15,15-16.
  • HUANG S: Rational drug discovery: what can we learn from regulatory networks? Drug Discov. Today (2002) 7(20 Suppl.):S163-S169.
  • DAVIDOV E, HOLLAND J, MARPLE E, NAYLOR S: Advancing drug discovery through systems biology. Drug Discov. Today (2003) 8(4):175-183.
  • APIC G, IGNJATOVIC T, BOYER S, RUSSELL RB: Illuminating drug discovery with biological pathways. FEBS Lett. (2005) 579(8):1872-1877.
  • SALWINSKI L, MILLER CS, SMITH AJ et al.: The database of interacting proteins: 2004 update. Nucl. Acids Res. (2004) 32(Suppl. 1):D449-D451.
  • BADER GD, BETEL D, HOGUE CW: BIND: the biomolecular interaction network database. Nucleic Acids Res. (2003) 31(1):248-250.
  • ZANZONI A, MONTECCHI-PALAZZI L, QUONDAM M et al.: MINT: a Molecular INTeraction database. FEBS Lett. (2002) 513(1):135-140.
  • UETZ P, GIOT L, CAGNEY G et al.: A comprehensive analysis of protein-protein interactions in Saccharomyces cerevisiae. Nature (2000) 403(6770):623-627.
  • GIOT L, BADER JS, BROUWER C et al.: A protein interaction map of Drosophila melanogaster. Science (2003) 302(5651):1727-1736.
  • STELZL U, WORM U, LALOWSKI M et al.: A human protein-protein interaction network: a resource for annotating the proteome. Cell (2005) 122(6):957-968.
  • RUAL JF, VENKATESAN K, HAO T et al.: Towards a proteome-scale map of the human protein-protein interaction network. Nature (2005) 437(7062):1173-1178.
  • MISHRA GR, SURESH M, KUMARAN K et al.: Human protein reference database - 2006 update. Nucleic Acids Res. (2006) 34(Database issue):D411-D414.
  • LEE TI, RINALDI NJ, ROBERT F et al.: Transcriptional regulatory networks in Saccharomyces cerevisiae. Science (2002) 298(5594):799-804.
  • PTACEK J, DEVGAN G, MICHAUD G et al.: Global analysis of protein phosphorylation in yeast. Nature (2005) 438(7068):679-684.
  • WINGENDER E, CHEN X, FRICKE E et al.: The TRANSFAC system on gene expression regulation. Nucleic Acids Res. (2001) 29(1):281-283.
  • WISHART DS, KNOX C, GUO AC et al.: DrugBank: a comprehensive resource for in silico drug discovery and exploration. Nucleic Acids Res. (2006) 34(Database issue):D668-D672.
  • KANEHISA M: The KEGG database. Novartis Found. Symp. (2002) 247:91-101; discussion 101-103, 119-128, 244-152.
  • JOSHI-TOPE G, GILLESPIE M, VASTRIK I et al.: Reactome: a knowledgebase of biological pathways. Nucleic Acids Res. (2005) 33(Database issue):D428-D432.
  • SHANNON P, MARKIEL A, OZIER O et al.: Cytoscape: a software environment for integrated models of biomolecular interaction networks. Genome Res. (2003) 13(11):2498-2504.
  • BREITKREUTZ BJ, STARK C, TYERS M: Osprey: a network visualization system. Genome Biol. (2003) 4(3):R22.
  • DAHLQUIST KD, SALOMONIS N, VRANIZAN K, LAWLOR SC, CONKLIN BR: GenMAPP, a new tool for viewing and analyzing microarray data on biological pathways. Nat. Genet. (2002) 31(1):19-20.
  • VAILAYA A, BLUVAS P, KINCAID R et al.: An architecture for biological information extraction and representation. Bioinformatics (2005) 21(4):430-438.
  • NOVICHKOVA S, EGOROV S, DARASELIA N: MedScan, a natural language processing engine for MEDLINE abstracts. Bioinformatics (2003) 19(13):1699-1706.
  • DARASELIA N, YURYEV A, EGOROV S et al.: Extracting human protein interactions from MEDLINE using a full-sentence parser. Bioinformatics (2004) 20(5):604-611.
  • GOLPON HA, COLDREN CD, ZAMORA MR et al.: Emphysema lung tissue gene expression profiling. Am. J. Respir. Cell Mol. Biol. (2004) 31(6):595-600.
  • YURYEV A: Targeting transcription factors in cell regulation. Expert Opin. Ther. Targets (2006) 10(3):345-349.
  • HANIFI-MOGHADDAM P, GIELEN SC, KLOOSTERBOER HJ et al.: Molecular portrait of the progestagenic and estrogenic actions of tibolone: behavior of cellular networks in response to tibolone. J. Clin. Endocrinol. Metab. (2005) 90(2):973-983.
  • GUPTA VK, WAGNER BJ: Dexamethasone induces changes in glucocorticoid receptor phosphorylation and gene expression in human lens epithelial cells. Invest. Ophthalmol. Vis. Sci. (2005) 46(5):1890.
  • LEHNHARDT M, KLEIN-HITPASS L, KUHNEN C et al.: Response rate of fibrosarcoma cells to cytotoxic drugs on the expression level correlates to the therapeutic response rate of fibrosarcomas and is mediated by regulation of apoptotic pathways. BMC Cancer (2005) 5:74.
  • RICKARDSON L, FRYKNAS M, DHAR S et al.: Identification of molecular mechanisms for cellular drug resistance by combining drug activity and gene expression profiles. Br. J. Cancer (2005) 93(4):483-492.
  • GIELEN SCJP, KUHNE LCM, EWING PC, BLOK LJ, BURGER CW: Tamoxifen treatment for breast cancer enforces a distinct gene-expression profile on the human endometrium: an exploratory study. Endocr. Relat. Cancer (2005) 12(4):1037-1049.

Websites

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.